BRAEBURN RX INC.
PLYMOUTH MEETING, PA

Braeburn Rx Inc., incorporated on April 26, 2016, as BRAEBURN PHARMACEUTICALS, INC., is headquartered at 450 Plymouth Rd, Plymouth Meeting, PA, with a mailing address in Delaware. The company, registered under the Florida Model Dos FLSA company status and filed as FORP (Foreign for profit), specializes in developing innovative pharmaceutical treatments to address opioid addiction through buprenorphine formulations. Braeburn is actively pursuing approval from regulatory authorities for its long-acting, weekly and monthly buprenorphine formulations known as CAM2038. These formulations are designed to mitigate the challenges of non-adherence seen with current therapies by providing healthcare providers greater control over dosing schedules and maintaining patient adherence from the first day of treatment onward. Braeburn's platform offers flexibility and customization, enabling integration with existing patient protocols which can be adjusted based on individual needs. This tailored approach aims to reduce abuse potential and diversion compared to daily addiction treatments. The company focuses significantly on clinical innovation while playing a leadership role in addressing opioid dependency through advanced pharmacological solutions. Beyond product development, Braeburn supports healthcare initiatives aligned with its mission and accepts community program applications from U.S. entities evaluated individually. Notable leaders include Dennis H Langer, MD, JD, Jerry Karabelas, Ph.D., serving as directors, alongside Louis Ricigliano, who acts as CFO. With an emphasis on evolving the treatment landscape for underserved populations, Braeburn envisions creating sustainable improvements in addiction management and recovery outcomes. For additional information, visit their website at braeburnpharmaceuticals.com.